Europe PMC / Molecular Genetics and Metabolism · Jul 2024
Preclinical study reported NtBuHA reduced AFSM accumulation, neuroinflammation, seizure burden, and improved motor function in Cln1-/- mice.
Utilizing monogenic disorders to inform and solve highly complex…
Company research
Public company, workplace, funding, and market signals
Overview
Circumvent Pharmaceuticals is a Portland-based biotech developing precision medicines for neurodegenerative disease, with an initial focus on CLN1 Batten disease. Its lead program centers on NtBuHA/CIRC825, a small-molecule PPT1/thioesterase mimetic intended to modulate protein palmitoylation and support oral treatment for rare pediatric neurodegeneration.
Primary product
NtBuHA (CIRC825), an oral small-molecule PPT1/thioesterase mimetic for CLN1 Batten disease
Founded
2017
Headquarters
Portland, Oregon, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Rare disease / neurodegenerative therapeutics
Offices
4640 SW Macadam Avenue Suite 200, Portland, OR 97239
Business model
preclinical drug development
grant-funded biotech R&D
orphan-disease therapeutic development
Funding
Stage
seed + grant-backed preclinical
Total raised
$7.3M
Latest round
Grant · Nov 2021
Latest amount
$2.9M
People & investors
Leadership
Andrew Lim
CEO
Devin Wiley
Co-founder, CMO and Head of Research and Development
Chief Scientific Officer
Program Director
Work & culture
Mission-driven and research-heavy, with a small cross-functional team of scientists and clinicians focused on rare neurodegenerative disease, patient advocacy partnerships, and translating preclinical findings toward clinical development.
Product & market
Pricing
Not publicly disclosed; pre-commercial and grant/seed funded.
Differentiators
- —Focus on CLN1 Batten disease and related rare neurodegenerative disorders
- —Targets protein palmitoylation/palmitoylome biology
- —Small-molecule PPT1 mimetic approach (NtBuHA/CIRC825)
- —Oral delivery concept rather than invasive biologics
- —Preclinical work suggests effects on neuroinflammation, seizures, and motor function
Customers
CLN1 Batten disease patients
caregivers and patient families
Batten disease advocacy organizations
clinical and academic research collaborators
Competitors
Denali Therapeutics
BioMarin Pharmaceutical
Fulcrum Therapeutics
Genentech
UCB
Scale & contact
Estimated revenue
$0.5M-$1M
Estimated monthly visits
1.8K
Latest news
HHS TAGGS · Sep 2021
NIH/NINDS Phase II SBIR award supporting GMP-ready chemistry, formulation, toxicology, safety pharmacology, and pre-IND work through June 2025.
HHS TAGGS · Jul 2021
NIH SBIR award extending the CIRC825 palmitoylation platform into Alzheimer’s disease models.
HHS TAGGS · Mar 2021
NIH Phase I award to develop a blood-based assay to monitor whether Circumvent’s experimental therapy is affecting the disease mechanism in CLN1.
Jobs and careers at Circumvent
0 jobs at Circumvent
No open positions
Check back later for new openings